#TechnologyForLicensing: CCAMP and the Institute of Plasma Research (IPR) have jointly filed a patent for their "𝐂𝐨𝐥𝐝 𝐀𝐭𝐦𝐨𝐬𝐩𝐡𝐞𝐫𝐢𝐜 𝐏𝐥𝐚𝐬𝐦𝐚-𝐁𝐚𝐬𝐞𝐝 (𝐂𝐀𝐏) 𝐀𝐢𝐫 𝐃𝐢𝐬𝐢𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐧 𝐃𝐞𝐯𝐢𝐜𝐞" The solution addresses limitations of existing technologies for air purification and is capable of: * Neutralising pathogens * Trapping/removing PM 2.5 and PM 10 particles, rendering improved ambient air quality * Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs. 𝐀𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐝𝐞𝐬𝐢𝐠𝐧: * The device has been validated on the ESKAPE range of bacterial pathogens, fungal pathogens and viral organisms by an independent NABL-accredited lab. * The device can be customised as a stand-alone or as an attachment with existing filtration devices and AHU systems. * It is scalable as the cartridge is modular, and the product can be scaled to suit the application area. Plasma Clean is the next-gen in air purification. If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT): 📧ott@ccamp.res.in @Taslimarif_IND @PrinSciAdvOff @DBTIndia @IndiaDST @BIRAC_2012 @kris_sg @honeywell @Dyson @BlueairUS @Bry_Air @IQAir @BlueStarLtd @carrier @DaikinIndia @johnsoncontrols @CamfilGroup

#TechnologyForLicensing: A novel topical formulation for treating pre-cancerous lesions/early-stage skin cancer in invasive squamous cell carcinoma (SCC), the second most common type of skin #cancer. 𝐓𝐡𝐞 𝐩𝐫𝐨𝐛𝐥𝐞𝐦 SCCs start as premalignant lesions called Actinic Keratoses (AKs), and the standard treatment involves the use of 5-fluorouracil (5-FU), a topical medication. However, 5-FU can cause severe side effects, including intense redness, itching, crusting, and pain. 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧 The novel topical formulation, developed and successfully tested by C-CAMP’s Discovery-to-Innovation Accelerator (DIA) program in collaboration with @DBT_CDFD on syngeneic mice and human xenograft models, showed significant tumour growth reduction with no toxicity in preliminary in vivo models. 𝐊𝐞𝐲 𝐩𝐫𝐨𝐩𝐞𝐫𝐭𝐢𝐞𝐬 This novel formulation comprises a novel component used alone or combined with 5-FU. The topical application showed no dermal toxicity in animal models. The molecule shows potent immunomodulatory and anti-inflammatory activity and significantly improved efficacy over 5-FU alone in vivo. If you are interested in knowing more and want to co-develop this with us, please reach out to the CCAMP Office of Technology Transfer (#OTT): ✉️ott@ccamp.res.in, dia_licensing@ccamp.res.in ☎️080 6718 5322 @Taslimarif_IND @PrinSciAdvGoI @DBTIndia @IndiaDST @BIRAC_2012 @kris_sg @abbvie @abcuro @cgoncology @ImmuneOnc @Roche @Novartis @NovartisCancer @AstraZeneca @bmsnews @pfizer @Amgen @AmgenOncology @PeptidreamInc @proteinqure @ferring @halozymeinc @GileadSciences @BostonONCOLOGY

🩻#TechnologyforLicensing: 𝐢𝐎𝐬𝐭𝐞𝐨𝐩𝐨𝐫𝐨𝐬 𝐒𝐜𝐫𝐞𝐞𝐧, a novel, AI-enhanced chest X-ray tool The tool forecasts #osteoporosis and its future risk for fracture at the hip and spine using a routine chest X-ray with high accuracy (93–98%). This innovation provides a quick (one-minute), cost-effective AI diagnostic for mass screening, even in resource-limited areas. We're open to discussing licensing or co-development partnerships with companies and industry stakeholders looking to make a global impact. To learn more about this #technology, please reach out to the CCAMP Office of Technology Transfer (#OTT): 🔗ccamp.res.in/ott-connect/ ☎️080 6718 5322 📍Office of Technology Transfer (OTT), Centre for Cellular and Molecular Platforms (C-CAMP), GKVK Post, Bellary Road, Bangalore 560065, Karnataka, India. @Taslimarif_IND @PrinSciAdvOff @DBTIndia @BIRAC_2012 @AIMtoInnovate @NITIAayog @GoI_MeitY @meitystartuphub @startupindia @ITBTGoK @Ktech_biotech @Startup_Kar @EpsilonLtd @hindrays @INDIA_RMS @GEHealthCare @PhilipsHealth @SiemensHealth @Harrison_ai @GoogleHealth @AstraZeneca @bmsnews #DiagnoHealthcare

#TechnologyForLicensing: CCAMP and Institute of Plasma Research (IPR) have jointly filed a patent for their "Cold Atmospheric Plasma-Based (CAP) Air Disinfection Device" The solution addresses limitations of existing technologies for air purification and is capable of: * Neutralising pathogens * Trapping/removing PM 2.5 and PM 10 particles rendering improved ambient air quality * Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs. Advantages of the design: * The device has been validated on the ESKAPE range of bacterial pathogens, fungal pathogens and viral organisms by an independent NABL-accredited lab. * The device can be customised as a stand-alone or as an attachment with existing filtration devices and AHU systems. * It is scalable as the cartridge is modular, and the product can be scaled to suit the application area. Plasma Clean is the next-gen in air purification. If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT): 📧ott@ccamp.res.in @Taslimarif_IND @PrinSciAdvOff @DBTIndia @BIRAC_2012 @kris_sg @honeywell @Dyson @BlueairUS @Bry_Air @IQAir @BlueStarLtd

🩻#TechnologyforLicensing: iOsteoporos Screen, a novel, AI-enhanced chest X-ray tool The tool forecasts #osteoporosis and its future risk for fracture at the hip and spine using a routine chest X-ray with high accuracy (93–98%). This innovation provides a quick (one-minute), cost-effective AI diagnostic for mass screening, even in resource-limited areas. We're open to discussing licensing or co-development partnerships with companies and industry stakeholders looking to make a global impact. To learn more about this #technology, please reach out to the CCAMP Office of Technology Transfer (#OTT): 🔗ccamp.res.in/ott-connect/ ☎️080 6718 5322 📍Office of Technology Transfer (OTT), Centre for Cellular and Molecular Platforms (C-CAMP), GKVK Post, Bellary Road, Bangalore 560065, Karnataka, India. @Taslimarif_IND @PrinSciAdvOff @DBTIndia @BIRAC_2012 @AIMtoInnovate @NITIAayog @GoI_MeitY @meitystartuphub @startupindia @ITBTGoK @Startup_Kar @EpsilonLtd @hindrays @INDIA_RMS @GEHealthCare @PhilipsHealth @SiemensHealth @Harrison_ai @GoogleHealth @AstraZeneca @bmsnews #DiagnoHealthcare

#TechnologyForLicensing: A novel topical formulation for treating pre-cancerous lesions/early-stage skin cancer in invasive squamous cell carcinoma (SCC), the second most common type of skin #cancer. 𝐓𝐡𝐞 𝐩𝐫𝐨𝐛𝐥𝐞𝐦 SCCs start as premalignant lesions called Actinic Keratoses (AKs), and the standard treatment involves the use of 5-fluorouracil (5-FU), a topical medication. However, 5-FU can cause severe side effects, including intense redness, itching, crusting, and pain. 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧 The novel topical formulation, developed and successfully tested by C-CAMP’s Discovery-to-Innovation Accelerator (DIA) program in collaboration with @DBT_CDFD on syngeneic mice and human xenograft models, showed significant tumour growth reduction with no toxicity in preliminary in vivo models. 𝐊𝐞𝐲 𝐩𝐫𝐨𝐩𝐞𝐫𝐭𝐢𝐞𝐬 This novel formulation comprises a novel component used alone or combined with 5-FU. The topical application showed no dermal toxicity in animal models. The molecule shows potent immunomodulatory and anti-inflammatory activity and significantly improved efficacy over 5-FU alone in vivo. If you are interested in knowing more and want to co-develop this with us, please reach out to the CCAMP Office of Technology Transfer (#OTT): ✉️ott@ccamp.res.in, dia_licensing@ccamp.res.in ☎️080 6718 5322 @Taslimarif @PrinSciAdvGoI @DBTIndia @IndiaDST @BIRAC_2012 @kris_sg @abbvie @abcuro @cgoncology @ImmuneOnc @Roche @Novartis @NovartisCancer @AstraZeneca @bmsnews @pfizer @Amgen @AmgenOncology @PeptidreamInc @proteinqure @ferring @halozymeinc @GileadSciences @BostonONCOLOGY

#TechnologyForLicensing We are looking for industry partners to scale up a novel immunomodulator in the #respiratory infection space. Developed and translated by the CCAMP translation research programme, Respi-Protect helps to prevent and treat respiratory infections such as the flu and COVID-19 through intranasal delivery. Respi-Protect's USP: A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections. What is the technology? It is an immunomodulatory peptide-based immune-boosting mechanism with broad-spectrum activity against viruses like Influenza and potentially SARS-CoV-2 How does it work? Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways. Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers. We invite #industry partners and other interested stakeholders to explore partnership opportunities with us. If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT): 📧ott@ccamp.res.in, dia_licensing@ccamp.res.in 📷080 6718 5322 @Taslimarif @PrinSciAdvOff @PrinSciAdvGoI @DBTIndia @IndiaDST @BIRAC_2012 @SiemensHealth @Boehringer @Novartis @NovartisIndia @biogen @EliLillyandCo @AurigenePharma @sanofi @IndiaSanofi @Cipla_Global @ZydusUniverse @benedicphar

#TechnologyForLicensing CCAMP and Institute of Plasma Research (IPR) have jointly filed a patent for their "Cold Atmospheric Plasma-Based (CAP) Air Disinfection Device" The solution addresses limitations of the existing technologies for air purification and is capable of: * Neutralising pathogens * Trapping/removing PM 2.5 and PM 10 particles rendering improved ambient air quality * Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs. Advantages of the design: * The device has been validated on the ESKAPE range of bacterial pathogens, fungal pathogens and viral organisms by an independent NABL-accredited lab. * The device can be customised as a stand-alone or as an attachment with existing filtration devices and AHU systems. * It is scalable as the cartridge is modular, and the product can be scaled to suit the application area. Plasma Clean is the next-gen in air purification. If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT): 📧ott@ccamp.res.in 📞080 6718 5322 @Taslimarif @PrinSciAdvOff @DBTIndia @BIRAC_2012 @kris_sg @honeywell @Dyson @BlueairUS @Bry_Air @IQAir @BlueStarLtd

#TechnologyForLicensing We are looking for industry partners to scale up a novel immunomodulator in the respiratory infection space. Developed and translated by the CCAMP translation research programme, Respi-Protect helps to prevent and treat respiratory infections such as the flu and COVID-19 through intranasal delivery. Respi-Protect's USP: A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections. What is the technology? It is an immunomodulatory peptide-based immune-boosting mechanism with broad-spectrum activity against viruses like Influenza and potentially SARS-CoV-2 How does it work? Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways. Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers. We invite #industry partners and other interested stakeholders to explore partnership opportunities with us. If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT): 📧ott@ccamp.res.in, dia_licensing@ccamp.res.in 📷080 6718 5322 @Taslimarif @BIRAC_2012 @PrinSciAdvOff @PrinSciAdvGoI @DBTIndia @IndiaDST @SiemensHealth @Boehringer @Novartis @NovartisIndia @biogen @EliLillyandCo @AurigenePharma @sanofi @IndiaSanofi @Cipla_Global @ZydusUniverse

#TechnologyForLicensing: Researchers at CCAMP, in collaboration with @BRIC_CDFD, have successfully developed & tested in mice a novel topical formulation that shows significantly accelerated complex wound healing through promoting regeneration of tissues! The Problem: The risk factor for complex foot ulcers is as high as 15-25% in diabetic patients, as per a global study conducted in 2018. Efficient wound healing is a major challenge in the case of diabetic wounds/ foot ulcers, pressure ulcers, and venous leg ulcers. Impaired wound healing greatly impacts physical, psychological, social, and economic aspects for patients, affecting their quality of life and even calling for amputations in certain difficult cases. Current Scenario: Frequent surgical debridement, antibiotic dressings, or recombinant growth factor injections are the solutions employed now. All have limitations ranging from the requirement of skilled medical personnel, secondary antimicrobial resistance, low efficacy and high cost. The new formulation's performance: On a head-to-head with a marketed product, in-vivo data showed that the two proprietary components of the new formulation have significantly better: a) Wound healing b) Collagen deposition in diabetic animals. We believe it will also be useful in the treatment of other complex wounds like pressure ulcers and burns. We are inviting licensing interests. To know more, please reach out to the CCAMP Office of Technology Transfer (#OTT): 📧ott@ccamp.res.in ☎️080 6718 5322 @Taslimarif @DBTIndia @PrinSciAdvOff @kris_sg @BIRAC_2012 @Convatec @MDT_Diabetes @cardinalhealth @SmithNephewPLC @integra_life @JNJNews @MiMedx @Coloplast_WCare @orgoholdingsinc @3M

#TechnologyForLicensing CCAMP and Institute of Plasma Research (IPR) have jointly filed a patent for their "Cold Atmospheric Plasma-Based (CAP) Air Disinfection Device" The solution addresses limitations of the existing technologies for air purification and is capable of: * Neutralising pathogens * Trapping/removing PM 2.5 and PM 10 particles rendering improved ambient air quality * Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs. Advantages of the design: * The device has been validated on the ESKAPE range of bacterial pathogens, fungal pathogens and viral organisms by an independent NABL-accredited lab. * The device can be customised as a stand-alone or as an attachment with existing filtration devices and AHU systems. * Plasma-Clean is scalable as the cartridge is modular, and the product can be scaled to suit the application area. Plasma Clean is the next-gen in air purification. If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT): 📧ott@ccamp.res.in 📞080 6718 5322 @Taslimarif @BIRAC_2012 @PrinSciAdvOff @DBTIndia @kris_sg @honeywell @Dyson @BlueairUS @Bry_Air @IQAir @BlueStarLtd

#TechnologyForLicensing We are looking for industry partners to scale up a novel immunomodulator in the respiratory infection space. Developed and translated by the CCAMP translation research programme, Respi-Protect helps to prevent and treat respiratory infections such as the flu and COVID-19 through intranasal delivery. Respi-Protect's USP: A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections. What is the technology? It is an immunomodulatory peptide-based immune-boosting mechanism with broad-spectrum activity against viruses like Influenza and potentially SARS-CoV-2 How does it work? Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways. Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers. We invite #industry partners and other interested stakeholders to explore partnership opportunities with us. If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT): 📧ott@ccamp.res.in, dia_licensing@ccamp.res.in 📷080 6718 5322 @Taslimarif @BIRAC_2012 @SiemensHealth @Boehringer @Novartis @NovartisIndia @biogen @EliLillyandCo @AurigenePharma @sanofi @IndiaSanofi @Cipla_Global @ZydusUniverse @PrinSciAdvOff @PrinSciAdvGoI @DBTIndia @IndiaDST

#TechnologyforLicensing: Introducing #PlasmaClean, a novel air purification plus decontamination technology. The solution addresses the limitations of the existing technologies for air purification and is capable of: 📌 Neutralising pathogens 📌Trapping/removing PM 2.5 and PM 10 particles rendering improved ambient air quality 📌Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs Advantages of design: 📌The device has been validated on the ESKAPE range of bacterial pathogens, fungal pathogens and viral organisms 📌It can be customised as a stand-alone as well as an attachment with existing filtration devices and AHU systems 📌The device is scalable as the cartridge is modular, and the product can be scaled for the application area If you are interested to know more, please reach out to the C-CAMP Office of Technology Transfer (#OTT): 📧 ott@ccamp.res.in, dia_licensing@ccamp.res.in ☎️080 6718 5322 @Taslimarif @DBTIndia @BIRAC_2012 @PrinSciAdvOff @kris_sg @honeywell @Dyson @BlueairUS @IQAir @BlueStarLtd @godrejaer @BreatheEasyLabs

#TechnologyForLicensing We are looking for industry partners to scale up a novel immunomodulator in the respiratory infection space. Developed and translated by the CCAMP translation research programme, Respi-Protect helps to prevent and treat respiratory infections such as the flu and COVID-19 through intranasal delivery. Respi-Protect's USP: A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections. What is the technology? It is an immunomodulatory peptide-based immune-boosting mechanism with broad-spectrum activity against viruses like Influenza and potentially SARS-CoV-2 How does it work? Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways. Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers. We invite #industry partners and other interested stakeholders to explore partnership opportunities with us. If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT): 📧ott@ccamp.res.in, dia_licensing@ccamp.res.in 📷080 6718 5322 @Taslimarif @BIRAC_2012 @SiemensHealth @Boehringer @Novartis @NovartisIndia @biogen @EliLillyandCo @AurigenePharma @sanofi @IndiaSanofi @Cipla_Global @ZydusUniverse @PrinSciAdvOff @PrinSciAdvGoI @DBTIndia @IndiaDST

#TechnologyforLicensing: Plasma Clean, a novel air purification plus decontamination technology. The solution addresses the limitations of the existing technologies for air purification and is capable of: 📌Neutralising pathogens 📌Trapping/removing PM2.5 & PM10 particles 📌Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs Advantages of design: *Validated on the ESKAPE range of bacterial pathogens, fungal pathogens & viral organisms *Can be customised as a stand-alone as well as an attachment with existing filtration devices & AHU systems *Scalable as the cartridge is modular and the product can be scaled for the application area Interested in knowing more? Please get in touch with the CCAMP Office of Technology Transfer (#OTT): 📧ott@ccamp.res.in, dia_licensing@ccamp.res.in ☎️080 6718 5322 @Taslimarif @BIRAC_2012 @PrinSciAdvOff @kris_sg @honeywell @Dyson @BlueairUS @Bry_Air @IQAir @BlueStarLtd @GodrejAppliance @BreatheEasyLabs @HuaweiIndia @Philips